Rani Therapeutics(NASDAQ) RANI

Rani makes capsules that deliver injected medicines by mouth instead of needle. Its technology helps people who need regular biologic drugs, like those with chronic diseases. The company aims to make treatment easier and less painful for patients.

Capsules, Not Needles: Rani’s Main Offerings

• RaniPill Capsule Platform: Oral capsule designed to deliver biologic drugs that are usually injected; targets patients needing regular biologic therapies. (100% of revenue from collaborations, not product sales)
• RT-101: Capsule for octreotide, used in treating neuroendocrine tumors and acromegaly; completed early clinical testing.
• RT-114: Capsule for GLP-1/GLP-2 dual agonist, aimed at obesity; early clinical trial started in December 2025.
• RT-111: Capsule for ustekinumab biosimilar, used for inflammatory diseases; completed early clinical testing.
• Collaboration Programs: Joint projects with pharmaceutical companies to develop capsules for rare diseases and other conditions.

Growth Spurts and Strategic Moves

• Entered major collaboration with Chugai Pharmaceutical in October 2025, including $10 million upfront payment.
• Launched Phase 1 trial for RT-114 (obesity) in December 2025.
• Secured licensing and supply deals with Celltrion for biosimilar drugs in 2023.
• Raised $60.3 million in private placement in October 2025, converting $6 million debt to equity.
• Discontinued two pipeline programs in 2026 to focus on higher-priority projects.

Why Rani Stands Out (Without Standing on a Soapbox)

Rani’s capsule platform aims to replace injections with oral delivery for complex drugs. Its technology can handle many types of biologic medicines, not just one. The company’s in-house manufacturing and global partnerships support rapid development and scale.

Five Things You Need to Know

• Revenue was $1.6 million in 2025, up 58.9% from 2024.
• Net loss was $41.0 million in 2025, improving 27.6% from 2024.
• Cash, cash equivalents, and securities totaled $49.7 million at December 31, 2025.
• No commercial product sales; all revenue comes from collaborations and services.
• Operating expenses fell 26.5% to $39.9 million in 2025.

Bottom Line

Rani has shifted from research to early clinical trials, focusing on oral delivery of injected drugs. The company relies on partnerships and careful spending as it works toward commercializing its capsule technology.